TOMTOM NV (TOM2.AS)

NL0013332471 - Common Stock

5.495  -0.02 (-0.45%)

Fundamental Rating

3

Overall TOM2 gets a fundamental rating of 3 out of 10. We evaluated TOM2 against 99 industry peers in the Software industry. While TOM2 seems to be doing ok healthwise, there are quite some concerns on its profitability. TOM2 is valued expensive and it does not seem to be growing.



2

1. Profitability

1.1 Basic Checks

In the past year TOM2 has reported negative net income.
TOM2 had a positive operating cash flow in the past year.
TOM2 had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: TOM2 reported negative operating cash flow in multiple years.

1.2 Ratios

TOM2's Return On Assets of -3.25% is on the low side compared to the rest of the industry. TOM2 is outperformed by 66.67% of its industry peers.
Looking at the Return On Equity, with a value of -16.44%, TOM2 is doing worse than 72.41% of the companies in the same industry.
Industry RankSector Rank
ROA -3.25%
ROE -16.44%
ROIC N/A
ROA(3y)-8.66%
ROA(5y)-0.8%
ROE(3y)-32.17%
ROE(5y)-13.59%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TOM2 has a Gross Margin of 85.14%. This is in the better half of the industry: TOM2 outperforms 78.16% of its industry peers.
In the last couple of years the Gross Margin of TOM2 has grown nicely.
TOM2 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.89%
GM growth 5Y3.9%

4

2. Health

2.1 Basic Checks

TOM2 does not have a ROIC to compare to the WACC, probably because it is not profitable.
TOM2 has less shares outstanding than it did 1 year ago.
TOM2 has less shares outstanding than it did 5 years ago.
The debt/assets ratio for TOM2 is higher compared to a year ago.

2.2 Solvency

The Debt to FCF ratio of TOM2 is 7.47, which is on the high side as it means it would take TOM2, 7.47 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of TOM2 (7.47) is comparable to the rest of the industry.
TOM2 has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
TOM2 has a Debt to Equity ratio (0.25) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 7.47
Altman-Z N/A
ROIC/WACCN/A
WACC6.97%

2.3 Liquidity

TOM2 has a Current Ratio of 1.85. This is a normal value and indicates that TOM2 is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of TOM2 (1.85) is better than 64.37% of its industry peers.
TOM2 has a Quick Ratio of 1.79. This is a normal value and indicates that TOM2 is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.79, TOM2 is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.79

3

3. Growth

3.1 Past

TOM2 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.71%.
TOM2 shows a decrease in Revenue. In the last year, the revenue decreased by -0.84%.
The Revenue has been decreasing by -3.17% on average over the past years.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-0.84%
Revenue growth 3Y3.45%
Revenue growth 5Y-3.17%
Sales Q2Q%-2.38%

3.2 Future

TOM2 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.92% yearly.
Based on estimates for the next years, TOM2 will show a small growth in Revenue. The Revenue will grow by 5.90% on average per year.
EPS Next Y51.71%
EPS Next 2Y69.42%
EPS Next 3Y53.92%
EPS Next 5YN/A
Revenue Next Year-1.67%
Revenue Next 2Y1.63%
Revenue Next 3Y2.75%
Revenue Next 5Y5.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOM2. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 39.47, TOM2 can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, TOM2 is valued a bit more expensive than the industry average as 60.92% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 23.53. TOM2 is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 39.47

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TOM2 is on the same level as its industry peers.
TOM2's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. TOM2 is more expensive than 60.92% of the companies in the same industry.
Industry RankSector Rank
P/FCF 115.11
EV/EBITDA 21.27

4.3 Compensation for Growth

TOM2's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TOM2's earnings are expected to grow with 53.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.42%
EPS Next 3Y53.92%

0

5. Dividend

5.1 Amount

TOM2 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TOMTOM NV

AMS:TOM2 (1/14/2025, 7:00:00 PM)

5.495

-0.02 (-0.45%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)10-11 2024-10-11/bmo
Earnings (Next)02-04 2025-02-04/amc
Inst Owners23.84%
Inst Owner ChangeN/A
Ins Owners53.12%
Ins Owner ChangeN/A
Market Cap686.88M
Analysts45
Price Target6.55 (19.2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)374.11%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-279.47%
Min EPS beat(2)-426.8%
Max EPS beat(2)-132.14%
EPS beat(4)1
Avg EPS beat(4)-163.94%
Min EPS beat(4)-426.8%
Max EPS beat(4)50.43%
EPS beat(8)4
Avg EPS beat(8)-71.94%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.1%
Min Revenue beat(2)-1.1%
Max Revenue beat(2)3.31%
Revenue beat(4)1
Avg Revenue beat(4)-1.89%
Min Revenue beat(4)-8.99%
Max Revenue beat(4)3.31%
Revenue beat(8)4
Avg Revenue beat(8)2.79%
Revenue beat(12)5
Avg Revenue beat(12)1.45%
Revenue beat(16)5
Avg Revenue beat(16)-0.13%
PT rev (1m)-12.7%
PT rev (3m)-12.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-410%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.49%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 39.47
P/S 1.19
P/FCF 115.11
P/OCF 54.81
P/B 4.87
P/tB N/A
EV/EBITDA 21.27
EPS(TTM)-0.19
EYN/A
EPS(NY)0.14
Fwd EY2.53%
FCF(TTM)0.05
FCFY0.87%
OCF(TTM)0.1
OCFY1.82%
SpS4.6
BVpS1.13
TBVpS-0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.25%
ROE -16.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.14%
FCFM 1.04%
ROA(3y)-8.66%
ROA(5y)-0.8%
ROE(3y)-32.17%
ROE(5y)-13.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.89%
GM growth 5Y3.9%
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 7.47
Debt/EBITDA 2.93
Cap/Depr 17.88%
Cap/Sales 1.14%
Interest Coverage N/A
Cash Conversion 103.22%
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.79
Altman-Z N/A
F-Score6
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)21.05%
Cap/Depr(5y)14.72%
Cap/Sales(3y)2.18%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y51.71%
EPS Next 2Y69.42%
EPS Next 3Y53.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.84%
Revenue growth 3Y3.45%
Revenue growth 5Y-3.17%
Sales Q2Q%-2.38%
Revenue Next Year-1.67%
Revenue Next 2Y1.63%
Revenue Next 3Y2.75%
Revenue Next 5Y5.9%
EBIT growth 1Y-110.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year175.85%
EBIT Next 3Y63.21%
EBIT Next 5YN/A
FCF growth 1Y-83.54%
FCF growth 3YN/A
FCF growth 5Y-32.14%
OCF growth 1Y-74.77%
OCF growth 3YN/A
OCF growth 5Y-32.25%